Biogen (NASDAQ:BIIB) stock rises as Q2 2025 results surpass expectations, driven by Alzheimer's drug Leqembi developed with ...

Investing.com - Shares of Biogen (NASDAQ:BIIB) rose in premarket U.S. trading on Thursday after the drugmaker posted ...

Biogen Inc. (NASDAQ:BIIB) reported on Thursday that the second quarter of 2025 adjusted earnings per share were $5.47, up 4% ...

Biotech company Biogen (NASDAQ:BIIB) will be reporting results this Thursday morning. Here’s what you need to know. Biogen ...

Biotech company Biogen (NASDAQ:BIIB) in Q2 CY2025, with sales up 7.3% year on year to $2.65 billion. Its non-GAAP profit of ...

Shares of biotech company Biogen (NASDAQ:BIIB) fell 3.1% in the morning session after analysts at Truist downgraded the stock ...

Q2 2025 Earnings Call Transcript July 31, 2025 Biogen Inc. misses on earnings expectations. Reported EPS is $ EPS, ...

Biogen (NASDAQ:BIIB) is scheduled to announce Q2 earnings results on Thursday, July 31st, before market open. The consensus EPS Estimate is $3.88 (-3.5% Y/Y) and the consensus Revenue Estimate is ...

CAMBRIDGE, Mass., June 30, 2025 (GLOBE NEWSWIRE) -- Biogen Inc. (Nasdaq: BIIB) – announced the initiation of dosing in the global clinical study, PROMINENT.

Inc. (Nasdaq: BIIB) announced topline results from the Phase 1 study of salanersen (BIIB115/ION306), an antisense oligonucleotide (ASO) being developed for the treatment of spinal muscular atrophy ...

Biogen Inc. (Nasdaq: BIIB) today announced new data that reinforce the clinical impact of nusinersen across a broad spectrum of individuals affected by spinal muscular atrophy (SMA).

Biogen BIIB initiated dosing in a global, late-stage study of its investigational candidate, felzartamab, for treating adult patients with primary membranous nephropathy (PMN). Top-line data ...